Avidity Biosciences Inc (RNA)

Avidity Biosciences' stock price has increased significantly in the past six months. As of January 7, 2026, the share price was $72.37, a 141.80% increase from January 8, 2025. The stock was up approximately 129.7% year-to-date as of December 8, 2025, and saw a roughly 49% 3-month share price return. The announcement of Novartis' acquisition of Avidity Biosciences on October 26, 2025, significantly impacted the stock. In the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought.

Avidity Biosciences is a pre-commercial biotechnology company, so traditional demand seasonality is not directly applicable. An analysis of Avidity Biosciences' seasonal stock chart over the past four years suggests a period of seasonal strength from May 13 to September 18, aligning with the broader Healthcare sector's seasonal strength from April 25 to December 4, but the limited data is insufficient to create a reliable seasonal profile.

Avidity Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing Antibody Oligonucleotide Conjugates (AOCs). Their AOC platform combines monoclonal antibodies with oligonucleotide therapies to target the root cause of diseases. The company has three programs in clinical development for rare muscle diseases, including Delpacibart etedesiran (AOC 1001) for myotonic dystrophy type 1, Delpacibart zotadirsen (AOC 1044) for Duchenne muscular dystrophy, and Delpacibart braxlosiran (AOC 1020) for facioscapulohumeral muscular dystrophy. Avidity is also expanding its research to include cardiac tissue and immune cells, developing precision cardiology candidates. The company generates revenue through research collaboration and licensing agreements.

Avidity Biosciences is headquartered in San Diego, California, and maintains research and development operations in the United States. Its direct operational footprint is primarily in the US, with collaborations extending the reach of its AOC technology.

Avidity Biosciences has a generally positive brand reputation due to its pioneering work in RNA-based therapeutics and its AOC platform. The company's focus on addressing serious neuromuscular and cardiac diseases has garnered investor interest and positive market sentiment. Analysts have given Avidity Biosciences a consensus rating of "Buy" or "Hold." The stock's strong performance over the past year reflects market confidence. There have been no specific events reported in the past year that have negatively impacted Avidity Biosciences' brand reputation.

Avidity Biosciences, Inc. is primarily controlled by institutional investors, who hold the vast majority of the stock. Major institutional owners include Fmr LLC, Janus Henderson Group Plc, and Vanguard Group Inc. Individual investors and public companies hold smaller percentages of the stock. Executives and directors have been net sellers over the past year.